Roivant Sciences Ltd., 10% Owner at Urovant Sciences Ltd. (UROV), bought 35,176 shares at $7.97 ($292K) on 2019-06-07, disclosed to the SEC on 2019-06-11.
Scheduled purchase ($292k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.96 | 6,649 | $53K | 18.1% |
| 2 | $7.97 | 6,649 | $53K | 18.2% |
| 3 | $8.35 | 7,500 | $63K | 21.4% |
| 4 | $8.58 | 7,189 | $62K | 21.1% |
| 5 | $8.58 | 7,189 | $62K | 21.1% |
| Total | $8.30 avg | 35,176 |
| $292K |
| 100% |
| Filing → |
| IMVT | BUY | 2023-10-04 | $58.0M | — | Filing → |
| IMVT | BUY | 2022-10-07 | $2.5M | — | Filing → |
| IMVT | BUY | 2020-09-04 | $12.5M | — | Filing → |